Please login to the form below
FDA awards grant for cancer drug study
The US FDA has awarded a $1.6m grant under its orphan drugs programme to a Alabama-based biotech company Egen to help the company with clinical trials of a potential new therapy for ovarian cancer
The US Food and Drug Administration (FDA) has awarded a $1.6m grant under its orphan drugs programme to a small, Alabama-based biotech company called Egen to help the company with clinical trials of a potential new therapy for ovarian cancer.
The four-year grant is intended to assist in the phase II clinical development of the privately held company's lead product, Egen-001, which is being developed for the treatment of advanced recurrent ovarian cancer.
The drug is an interleukin-12 (IL-12) gene formulated with a biocompatible delivery polymer. IL-12 enhances the body's immune system against cancer and inhibits tumour blood supply, according to Egen.
The product has completed two phase I trials: one as monotherapy in platinum-resistant ovarian cancer patients, and the other in combination with carboplatin/docetaxel chemotherapy in platinum-sensitive ovarian cancer patients.
The FDA granted orphan drug status to Egen-001 in 2005. The status, which is reserved for drugs intended to treat diseases that affect fewer than 200,000 Americans, carries a number of benefits, including seven years of US marketing exclusivity, tax breaks and eligibility for help with clinical trial costs.
This is Egen's second grant for the drug from the FDA. The first, totaling $1m, was awarded in 2005.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Pfizer CEO pushes back COVID-19 vaccine submission to November
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
- The Truth about Doctors
- Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses
- Novartis scores CHMP backing for cholesterol drug Leqvio
- Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- Vaccine developers call on FDA to offer clarity on COVID-19 trials
- The other side of … blood cancer
- COVID-19 – a catalyst for technology adoption in clinical trials
PMHub
Frontera Group
Welcome to Frontera Group, where our agencies immerse you in the world of the patient...
Latest intelligence
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
- The other side of … blood cancer
- To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
- COVID-19 – a catalyst for technology adoption in clinical trials
- As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...
Quick links
Infographics
